Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Outlicenses Two CCR5 Antagonists To Newly Formed Tobira

This article was originally published in The Pink Sheet Daily

Executive Summary

TAK-652’s potential for once-daily dosing could make it the best-in-class oral CCR5 antagonist, Tobira’s CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Takeda, Santhera Extend Partnership On Idebenone To Duchenne Muscular Dystrophy

Takeda and the Swiss specialty pharma Santhera Pharmaceuticals are extending an existing collaboration on SNT-MC17 (idebenone) for the neuromuscular disease Friedreich's Ataxia to include a second indication for Duchenne muscular dystrophy, the firms announced Aug. 2

Takeda, Santhera Extend Partnership On Idebenone To Duchenne Muscular Dystrophy

Takeda and the Swiss specialty pharma Santhera Pharmaceuticals are extending an existing collaboration on SNT-MC17 (idebenone) for the neuromuscular disease Friedreich's Ataxia to include a second indication for Duchenne muscular dystrophy, the firms announced Aug. 2

Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists

Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel